$9346 | SAVE $1,649 | Single User
$18692 | SAVE $3,298 | Site License
$28037 | SAVE $4,948 | Enterprise License

PharmaPoint: Renal Cell Carcinoma - Global Drug Forecast and Market Analysis to 2023
[Published by Global Data]

Published by Global Data: 21 Apr 2016 | 27020 | In Stock
Related Topics: Renal Cell Carcinoma

Introduction

PharmaPoint: Renal Cell Carcinoma - Global Drug Forecast and Market Analysis to 2023

Summary

Renal cell carcinoma (RCC) is among the 10 most frequently occurring cancers in Western countries. The RCC market is currently dominated by anti-angiogenic agents and tyrosine kinase inhibitors (TKIs) in particular, but it will experience dramatic changes over the forecast period as patents expire and promising new therapies enter the market. A large share of the RCC market is currently dominated by a few large companies, but they will struggle to retain these shares as they are joined by new entrants. One of these new entrants, Opdivo, is expected to have the largest market share by 2023. The different lines of treatment will offer up different battlegrounds and niches for companies, large and small, to compete for. The battle for the first-line of therapy is expected to be fierce, with three programmed death protein 1 (PD-1)/programmed death ligand 1 (PD-L1)-containing combination therapies backed by large companies lining up to compete. Out of this competition, new standards of care are expected to emerge for the different lines of treatment. There will also be a number of unmet needs still remaining at the end of the forecast period, and with that, the opportunity for pipeline drugs to carve out a niche in the RCC space.

Highlights

Key Questions Answered

- The RCC market is marked by the presence of a number of unmet needs. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of RCC market?

- The late-stage RCC pipeline has therapies targeting different lines of therapy. Which drugs will have the biggest impact in each RCC setting? Which of these drugs will have the highest peak sales at the highest CAGR, and why?

- Current therapies used to treat RCC include tyrosine kinase inhibitors and mTOR inhibitors. What will be the impact of the patent expiry of the current standard of care? How will the advent of new therapies change the drug treatment landscape for RCC? How will new drug combinations change the treatment paradigm of RCC? What are the key drivers and barriers to this change?

Key Findings

- The main drivers of the growth of the RCC market will be the launch of Opdivo in second-line setting and PD-1 modulator combinations in the first-line setting. GlobalData forecasts significant patient uptake for Opdivo, which will supersede tyrosine kinase inhibitors and mTOR inhibitors to become the SoC in second-line setting.

- The approval of immunotherapy in monotherapy or in combination with other agents will partially fulfil key unmet needs in the RCC space: however, many of these unmet needs will still remain even after these agents are launched.

- Another driver of the RCC market is the increasing incidence of RCC cases within the 8MM. The biggest constrainer of the RCC market is the launch of generics of tyrosine kinase inhibitors currently established as standard of care in most markets.

Scope

- Overview of RCC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

- Annualized RCC therapeutics market revenue, average cost of therapy and treatment usage pattern data from 2013 and forecast for ten years to 2023.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the RCC therapeutics market.

- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

- Analysis of the current and future market competition in the global RCC therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.

- Develop business strategies by understanding the trends shaping and driving the global RCC therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global RCC therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Track drug sales in the global RCC therapeutics market from 2013-2023.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents
for PharmaPoint: Renal Cell Carcinoma - Global Drug Forecast and Market Analysis to 2023 [Published by Global Data]

  • 1 Table of Contents

    1 Table of Contents 8

    1.1 List of Tables 15

    1.2 List of Figures 21

    2 Introduction 24

    2.1 Catalyst 24

    2.2 Related Reports 24

    2.3 Upcoming Related Reports 25

    3 Disease Overview 26

    3.1 Etiology and Pathophysiology 26

    3.1.1 Etiology 26

    3.1.2 Pathophysiology 26

    3.2 Clinical Staging 27

    3.3 Symptoms 28

    3.4 Prognostic Models 29

    3.5 Potential Biomarkers 30

    4 Epidemiology 31

    4.1 Disease Background 31

    4.2 Risk Factors and Comorbidities 31

    4.3 Global Trends 33

    4.3.1 Incidence 33

    4.3.2 Survival Rates for RCC - 8MM 35

    4.4 Forecast Methodology 36

    4.4.1 Sources Used 38

    4.4.2 Sources Not Used 41

    4.4.3 Forecast Assumptions and Methods for RCC Diagnosed Incident Cases 41

    4.4.4 Forecast Assumptions and Methods for RCC Five-Year Diagnosed Prevalent Cases 42

    4.4.5 Forecast Assumptions and Methods for RCC by Clinical Stage at Diagnosis 43

    4.5 Epidemiological Forecast of RCC (2013-2023) 44

    4.5.1 Diagnosed Incident Cases of RCC 44

    4.5.2 Age-Specific Diagnosed Incident Cases of RCC 45

    4.5.3 Sex-Specific Diagnosed Incident Cases of RCC 47

    4.5.4 Age-Standardized Diagnosed Incidence of RCC 49

    4.5.5 Diagnosed Incident Cases of RCC by Clinical Stage at Diagnosis 51

    4.5.6 Five-Year Diagnosed Prevalent Cases of RCC 52

    4.6 Discussion 53

    4.6.1 Epidemiological Forecast Insight 53

    4.6.2 Limitations of the Analysis 54

    4.6.3 Strengths of the Analysis 54

    5 Disease Management 56

    5.1 Diagnosis and Treatment Overview 56

    5.1.1 Screening and Diagnosis 56

    5.1.2 Surgical Management of RCC 56

    5.1.3 Treatment Guidelines and Leading Prescribed Drugs 57

    5.1.4 Clinical Practice 59

    5.2 US 64

    5.2.1 Diagnosis and Surgical Management 64

    5.2.2 Clinical Practice (Drug Treatment) 65

    5.3 France 66

    5.3.1 Diagnosis and Surgical Management 66

    5.3.2 Clinical Practice (Drug Treatment) 67

    5.4 Germany 67

    5.4.1 Diagnosis and Surgical Management 68

    5.4.2 Clinical Practice (Drug Treatment) 68

    5.5 Italy 69

    5.5.1 Diagnosis and Surgical Management 69

    5.5.2 Clinical Practice (Drug Treatment) 70

    5.6 Spain 71

    5.6.1 Diagnosis and Surgical Management 71

    5.6.2 Clinical Practice (Drug Treatment) 72

    5.7 UK 73

    5.7.1 Diagnosis and Surgical Management 73

    5.7.2 Clinical Practice (Drug Treatment) 74

    5.8 Japan 75

    5.8.1 Diagnosis and Surgical Management 75

    5.8.2 Clinical Practice (Drug Treatment) 76

    5.9 China 77

    5.9.1 Diagnosis and Surgical Management 78

    5.9.2 Clinical Practice (Drug Treatment) 78

    6 Competitive Assessment 79

    6.1 Overview 79

    6.2 Product Profiles - Major Brands 79

    6.2.1 Sutent (sunitinib) 79

    6.2.2 Nexavar (sorafenib) 87

    6.2.3 Votrient (pazopanib) 93

    6.2.4 Avastin (bevacizumab) 101

    6.2.5 Torisel (temsirolimus) 106

    6.2.6 Inlyta (axitinib) 112

    6.2.7 Afinitor (everolimus) 118

    6.2.8 Interferon-alfa 123

    6.2.9 Interleukin-2 126

    6.2.10 Tarceva (erlotinib) 128

    7 Unmet Needs and Opportunities 130

    7.1 Overview 130

    7.2 Challenge the Resistance to Metastatic RCC Treatments With New Targeted Agents Improving the Survival of Metastatic RCC Patients 130

    7.2.1 Unmet Need 130

    7.2.2 Gap Analysis 131

    7.2.3 Opportunity 132

    7.3 Drugs With Improved Tolerability Profiles 133

    7.3.1 Unmet Need 133

    7.3.2 Gap Analysis 133

    7.3.3 Opportunity 135

    7.4 More Efficacious Therapies for the Treatment of Unfavorable Risk Metastatic RCC 135

    7.4.1 Unmet Need 135

    7.4.2 Gap Analysis 136

    7.4.3 Opportunity 136

    7.5 Targeted Therapies for Non-Clear Cell RCC 137

    7.5.1 Unmet Need 137

    7.5.2 Gap Analysis 138

    7.5.3 Opportunity 139

    7.6 Novel Adjuvant Therapies for Non-Metastatic RCC 140

    7.6.1 Unmet need 140

    7.6.2 Gap Analysis 140

    7.6.3 Opportunity 142

    7.7 Biomarkers 143

    7.7.1 Overview 143

    7.7.2 Gap Analysis 143

    7.7.3 Opportunity 145

    8 Pipeline Assessment 147

    8.1 Overview 147

    8.2 Promising Drugs in Clinical Development 148

    8.2.1 Opdivo (nivolumab) and Yervoy (ipilimumab) 151

    8.2.2 Atezolizumab 161

    8.2.3 Cometriq (cabozantinib) 168

    8.2.4 IMA901 175

    8.2.5 AGS-003 (rocapuldencel-t) 177

    8.2.6 Tivozanib 183

    8.2.7 Lenvima (lenvatinib) 191

    8.2.8 Avelumab 196

    9 Promising Approaches in Early-Stage Development 202

    9.1 Keytruda (pembrolizumab) 202

    9.1.1 Overview 202

    9.2 Dalantercept (ACE-041) 203

    9.2.1 Overview 203

    9.3 Archexin (RX-021) 203

    9.3.1 Overview 203

    9.4 Other Drugs in Development 203

    10 Current and Future Players 205

    10.1 Overview 205

    10.2 Trends in Corporate Strategy 207

    10.3 Company Profiles 208

    10.3.1 Pfizer 208

    10.3.2 Novartis 212

    10.3.3 Bayer 213

    10.3.4 Roche 215

    10.3.5 Bristol-Myers Squibb 218

    10.3.6 Merck & Co. 220

    10.3.7 Exelixis 222

    10.3.8 Eisai 223

    10.3.9 AVEO Oncology 225

    10.3.10 Argos Therapeutics 227

    11 Market Outlook 230

    11.1 Global Markets 230

    11.1.1 Forecast 230

    11.1.2 Drivers and Barriers - Global Issues 236

    11.2 US 239

    11.2.1 Forecast 239

    11.2.2 Key Events 244

    11.2.3 Drivers and Barriers 245

    11.3 5EU 246

    11.3.1 Forecast 246

    11.3.2 Key Events 251

    11.3.3 Drivers and Barriers 252

    11.4 Japan 253

    11.4.1 Forecast 253

    11.4.2 Key Events 257

    11.4.3 Drivers and Barriers 257

    11.5 China 259

    11.5.1 Forecast 259

    11.5.2 Key Events 263

    11.5.3 Drivers and Barriers 263

    12 Appendix 265

    12.1 Bibliography 265

    12.2 Abbreviations 289

    12.3 Methodology 295

    12.4 Forecasting Methodology 295

    12.4.1 Diagnosed RCC Patients 295

    12.4.2 Percent Drug-Treated Patients 296

    12.4.3 Drugs Included in Each Therapeutic Class 297

    12.4.4 Launch and Patent Expiration Dates 298

    12.4.5 General Pricing Assumptions 299

    12.4.6 Average Body Weight and Surface Area Across the 8MM 300

    12.4.7 General Forecast Assumptions 300

    12.4.8 Individual Drug Assumptions 301

    12.4.9 Generic Erosion 307

    12.4.10 Pricing of Pipeline Agents 307

    12.5 Primary Research - KOLs Interviewed for This Report 314

    12.6 Primary Research - High-Prescribers Surveyed for this Report 316

    12.7 About the Authors 317

    12.7.1 Author 317

    12.7.2 Epidemiologist 318

    12.7.3 Therapy Director 319

    12.7.4 Global Director of Therapy Analysis and Epidemiology 319

    12.7.5 Global Head of Healthcare 320

    12.8 About GlobalData 321

    12.9 Disclaimer 321

List Of Tables
in PharmaPoint: Renal Cell Carcinoma - Global Drug Forecast and Market Analysis to 2023 [Published by Global Data]

1.1 List of Tables

Table 1: Classifications of RCC 27

Table 2: TNM and Staging Classification System for RCC 28

Table 3: Symptoms of RCC 29

Table 4: Risk Factors and Comorbidities for RCC 32

Table 5: Trends in the Age-Adjusted Incidence of Kidney Cancers in the US, Ages ≥20 Years, 1993-2007 33

Table 6: Trends in the Age-Adjusted Incidence of Kidney Cancers in the 5EU, Ages ≥20 Years, 1993-2007 34

Table 7: Trends in the Age-Adjusted Incidence of Kidney Cancers in Japan, Ages ≥20 Years, 1993-2007 34

Table 8: Trends in the Age-Adjusted Incidence of Kidney Cancers in Urban China, Ages ≥20 Years, 1993-2007 35

Table 9: Trends in the Five-Year Relative Survival (%) of Kidney Cancers in the 8MM, Both Sexes, 1993-2007 36

Table 10: 8MM, Sources of Epidemiological Data Used for the Forecast for RCC Diagnosed Incident Cases 37

Table 11: 8MM, Sources of Epidemiological Data Used for the Forecast for RCC Diagnosed Five-Year Prevalent Cases 37

Table 12: 8MM, Sources of Epidemiological Data Used for the Segmentation of RCC Incident Cases by Clinical Stage at Diagnosis 38

Table 13: 8MM, Diagnosed Incident Cases of RCC, Both Sexes, Ages ≥20 Years, N, 2013-2023 44

Table 14: 8MM, Age-Specific Diagnosed Incident Cases of RCC, Both Sexes, N (Row %), 2013 46

Table 15: 8MM, Sex-Specific Diagnosed Incident Cases of RCC, Ages ≥20 Years, N (Row %), 2013 48

Table 16: 8MM, Five-Year Diagnosed Prevalent Cases of RCC, Both Sexes, Ages ≥20 Years, N, 2013-2023 52

Table 17: Treatment Guidelines for RCC 58

Table 18: Most Prescribed Drugs for RCC by Class in the 8MM 59

Table 19: Country Profile - US 64

Table 20: Country Profile - France 66

Table 21: Country Profile - Germany 67

Table 22: Country Profile - Italy 69

Table 23: Country Profile - Spain 71

Table 24: Country Profile - UK 73

Table 25: Country Profile - Japan 75

Table 26: Country Profile - China 77

Table 27: Leading Treatments for RCC, 2015 79

Table 28: Product Profile - Sutent (sunitinib) 80

Table 29: Results of the Trial Comparing Sutent Versus IFN-alfa 83

Table 30: Summary of AEs from the Trial of Sutent Versus IFN-alfa 85

Table 31: Sutent SWOT Analysis, 2014 86

Table 32: Global Sales Forecasts ($m) for Sutent 2013-2023 87

Table 33: Product Profile - Nexavar (sorafenib) 88

Table 34: Results of the Trial Comparing Nexavar Versus Placebo 90

Table 35: Summary of AEs from the Trial of Nexavar versus Placebo 91

Table 36: Nexavar SWOT Analysis, 2014 92

Table 37: Global Sales Forecast ($m) for Nexavar, 2013-2023 93

Table 38: Product Profile - Votrient (pazopanib) 94

Table 39: Results of the Trial Comparing Votrient Versus Placebo 96

Table 40: Summary of the Results of the Trials Comparing Votrient Versus Sutent 97

Table 41: Summary of AEs from the Trial of Votrient Versus Sutent 99

Table 42: Votrient SWOT Analysis, 2014 100

Table 43: Global Sales Forecast ($m) for Votrient, 2013-2023 101

Table 44: Product Profile - Avastin (bevacizumab) 102

Table 45: Results of the Trial Comparing Avastin + IFN-alfa Versus IFN-alfa + Placebo 103

Table 46: Summary of AEs from the Trial of Avastin + IFN-alfa Versus IFN-alfa + placebo 104

Table 47: Avastin SWOT Analysis, 2014 105

Table 48: Global Sales Forecasts ($m) for Avastin, 2013-2023 106

Table 49: Product Profile - Torisel (temsirolimus) 107

Table 50: Results of the Trial Comparing Torisel Versus IFN-alfa Versus Torisel + IFN-alfa 108

Table 51: Summary of AEs from the Trial Comparing Torisel Versus IFN-alfa Versus Torisel + IFN-alfa 110

Table 52: Torisel SWOT Analysis, 2014 111

Table 53: Global Sales Forecasts ($m) for Torisel, 2013-2023 112

Table 54: Product Profile - Inlyta (axitinib) 113

Table 55: Results of the Trial Comparing Inlyta Versus Nexavar 115

Table 56: Summary of AEs from the Trial Comparing Inlyta Versus Nexavar 116

Table 57: Inlyta SWOT Analysis, 2014 117

Table 58: Global Sales Forecasts ($m) for Inlyta, 2013-2023 118

Table 59: Product Profile - Afinitor (everolimus) 119

Table 60: Results of the Record-1 Trial Comparing Afinitor Versus Placebo 120

Table 61: Summary of AEs from the Trial Comparing Afinitor Versus Placebo 121

Table 62: Afinitor SWOT Analysis 122

Table 63: Global Sales Forecasts ($m) for Afinitor, 2013-2023 123

Table 64: Results of the Trial Comparing IFN-alfa Versus IFN-alfa + vinblastine 124

Table 65: Summary of AEs from the Trial of IFN-alfa 125

Table 66: Results of the Trial Comparing High-Dose IL-2 Versus IL-2 + IFN-alfa 127

Table 67: Summary of AEs from the High-Dose IL-2 Versus IL-2 + IFN-alfa Trial 128

Table 68: Selected placebo-controlled, randomized adjuvant RCC trials 141

Table 69: Comparison of Therapeutic Classes in Development for RCC, 2016 151

Table 70: Product Profile - Opdivo (nivolumab) 152

Table 71: Product Profile - Yervoy (imilimumab) 152

Table 72: Efficacy of Opdivo in the CheckMate 025 Trial 154

Table 73: Efficacy of Opdivo + Yervoy, Opdivo + Stutent, and Opdivo + Votrient 156

Table 74: Safety of Opdivo and Afinitor from the CheckMate 025 Trial 157

Table 75: Safety Profile of Opdivo + Yervoy, Opdivo + Sutent, and Opdivo + Votrient 158

Table 76: Opdivo (monotherapy or combination with Yervoy) SWOT Analysis, 2016 160

Table 77: Global Sales Forecasts ($M) for Opdivo, 2013-2023 161

Table 78: Product Profile - Atezolizumab 162

Table 79: Efficacy of Atezolizumab 164

Table 80: Efficacy of Atezolizumab + Avastin combination therapy 164

Table 81: Safety of Atezolizumab in Phase Ib Study 165

Table 82: Atezolizumab SWOT Analysis, 2016 167

Table 83: Global Sales Forecasts ($M) for Atezolizumab, 2013-2023 168

Table 84: Product Profile - Cometriq (cabozantinib) 169

Table 85: Efficacy of Cometriq in the Phase III METEOR Trial 171

Table 86: Safety of Cometriq 172

Table 87: Cometriq SWOT Analysis, 2016 174

Table 88: Global Sales Forecasts ($M) for Cometriq, 2013-2023 175

Table 89: Product Profile - IMA901 176

Table 90: Efficacy of IMA901 in the Phase III IMPRINT Trial 176

Table 91: Product Profile - AGS-003 178

Table 92: AGS-003 SWOT Analysis, 2016 182

Table 93: Global Sales Forecasts ($M) for AGS-003, 2013-2023 183

Table 94: Product Profile - Tivozanib 185

Table 95: Efficacy of Tivozanib 186

Table 96: Safety of Tivozanib 187

Table 97: Safety profile of Tivozanib over time 188

Table 98: Tivozanib SWOT Analysis, 2016 190

Table 99: Global Sales Forecasts ($M) for Tivozanib, 2013-2023 191

Table 100: Product Profile - Lenvima (lenvatinib) 192

Table 101: Efficacy of Lenvima 193

Table 102: Lenvima SWOT Analysis, 2016 195

Table 103: Global Sales Forecasts ($M) for Lenvima, 2013-2023 196

Table 104: Product Profile - Avelumab 197

Table 105: Avelumab (in combination with Inlyta) SWOT Analysis, 2016 200

Table 106: Global Sales Forecasts ($M) for Avelumab, 2013-2023 201

Table 107: Drug Candidates in Early Development, 2016 204

Table 108: Key Companies in the RCC Market in the 8MM, 2013-2023 205

Table 109: Pfizer’s RCC Portfolio Assessment, 2016 210

Table 110: Novartis’ RCC Portfolio Assessment, 2016 212

Table 111: Bayer’s RCC Portfolio Assessment, 2016 214

Table 112: Roche’s RCC Portfolio Assessment, 2016 216

Table 113: BMS’ RCC Portfolio Assessment, 2016 219

Table 114: Merck & Co.’s RCC Portfolio Assessment, 2016 220

Table 115: Exelixis’ RCC Portfolio Assessment, 2016 222

Table 116: Eisai RCC Portfolio Assessment, 2016 224

Table 117: AVEO Oncology’s RCC Portfolio Assessment, 2016 226

Table 118: Argos Therapeutics’ RCC Portfolio Assessment, 2016 228

Table 119: Sales Forecasts ($m) for Renal Cell Carcinoma in the Global Markets, 2013-2023 230

Table 120: RCC Market Drivers and Barriers, 2013-2023 236

Table 121: Sales Forecasts ($m) for Renal Cell Carcinoma in the United States, 2013-2023 240

Table 122: Key Events Impacting Sales for RCC in the US, 2016 244

Table 123: US RCC Market Drivers and Barriers, 2016 245

Table 124: Sales Forecasts ($m) for Renal Cell Carcinoma in 5EU, 2013-2023 247

Table 125: Key Events Impacting Sales for RCC in 5EU, 2016 251

Table 126: 5EU RCC Market Drivers and Barriers, 2016 252

Table 127: Sales Forecasts ($m) for Renal Cell Carcinoma in Japan, 2013-2023 254

Table 128: Key Events Impacting Sales for RCC in Japan, 2016 257

Table 129: Japan RCC Market - Drivers and Barriers, 2016 257

Table 130: Sales Forecasts ($m) for Renal Cell Carcinoma in China, 2013-2023 260

Table 131: Key Events Impacting Sales for RCC in China, 2016 263

Table 132: China RCC Market - Drivers and Barriers, 2016 263

Table 133: RCC Incidence, 2013-2023 296

Table 134: RCC, Key Launch Dates 298

Table 135: RCC, Key Patent Expiries 298

Table 136: Average Body Weight and Surface Area Across the 8MM 300

Table 137: Average Cost of Therapy of Sutent 302

Table 138: Average Cost of Therapy of Votrient 303

Table 139: Average Cost of Therapy of Nexavar 304

Table 140: Average Cost of Therapy of Avastin 304

Table 141: Average Cost of Therapy of Inlyta 305

Table 142: Average Cost of Therapy of Torisel 306

Table 143: Average Cost of Therapy of Afinitor 307

Table 144: Average Cost of Therapy of Opdivo 308

Table 145: Average Cost of Therapy of Yervoy + Opdivo 308

Table 146: Average Cost of Therapy of Atezolizumab 309

Table 147: Average Cost of Therapy of Avelumab 310

Table 148: Average Cost of Therapy of Cometriq 311

Table 149: Average Cost of Therapy of Lenvima 312

Table 150: Average Cost of Therapy of tivozanib 312

Table 151: Average Cost of Therapy of AGS-003 313

Table 152: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 316

List Of Figures, Charts and Diagrams
in PharmaPoint: Renal Cell Carcinoma - Global Drug Forecast and Market Analysis to 2023 [Published by Global Data]

1.2 List of Figures

Figure 1: 8MM, Diagnosed Incident Cases of RCC, Both Sexes, Ages ≥20 Years, N, 2013-2023 45

Figure 2: 8MM, Age-Specific Diagnosed Incident Cases of RCC, Both Sexes, N, 2013 47

Figure 3: 8MM, Sex-Specific Diagnosed Incident Cases of RCC, Ages ≥20 Years, N, 2013 49

Figure 4: 8MM, Age-Standardized Diagnosed Incidence of RCC (Cases per 100,000 Population), Ages ≥20 Years, by Sex, 2013 50

Figure 5: 8MM, Diagnosed Incident Cases of RCC by Clinical Stage at Diagnosis, Ages ≥20 Years, N, 2013 51

Figure 6: 8MM, Five-Year Diagnosed Prevalent Cases of RCC, Both Sexes, Ages ≥20 Years, N, 2013-2023 53

Figure 7: Treatment Algorithm for RCC 63

Figure 8: RCC - Phase III Pipeline, 2013-2023 149

Figure 9: Competitive Assessment of Late-Stage Pipeline Agents in RCC, 2013-2023 150

Figure 10: Opdivo’s Development in RCC 154

Figure 11: Clinical and Commercial Positioning of Opdivo 159

Figure 12: Atezolizumab’s Development in RCC 162

Figure 13: Clinical and Commercial Positioning of Atezolizumab 166

Figure 14: Cometriq’s Development in RCC 170

Figure 15: Clinical and Commercial Positioning of Cometriq 173

Figure 16: AGS-003’s Development in RCC 179

Figure 17: Clinical and Commercial Positioning of AGS-003 181

Figure 18: Tivozanib’s Development in RCC 185

Figure 19: Clinical and Commercial Positioning of Tivozanib 189

Figure 20: Lenvima’s Development in RCC 192

Figure 21: Clinical and Commercial Positioning of Lenvima 194

Figure 22: Avelumab’s Development in RCC 198

Figure 23: Clinical and Commercial Positioning of Avelumab 199

Figure 24: Global Sales of Branded Products for aRCC by Company, 2013-2023 206

Figure 25: Company Portfolio Gap Analysis in RCC, 2013-2023 207

Figure 26: Pfizer SWOT Analysis in RCC, 2014 211

Figure 27: Novartis SWOT Analysis in RCC, 2014 213

Figure 28: Bayer SWOT Analysis in RCC, 2014 215

Figure 29: Roche SWOT Analysis in RCC, 2014 217

Figure 30: Bristol-Myers Squibb SWOT Analysis in RCC, 2014 219

Figure 31: Merck & Co SWOT Analysis in RCC, 2014 221

Figure 32: Exelexis SWOT Analysis in RCC, 2014 223

Figure 33: Eisai SWOT Analysis in RCC, 2014 225

Figure 34: AVEO Oncology SWOT Analysis in RCC, 2014 227

Figure 35: Argos Therapeutics SWOT Analysis in RCC, 2014 229

Figure 36: Global Sales for aRCC by Region, 2013-2023 233

Figure 37: Global sales for aRCC by Class, 2013-2023 234

Figure 38: Global Sales for aRCC by Brand, 2013-2023 235

Figure 39: Sales for aRCC in the US by Class, 2013-2023 242

Figure 40: Sales for aRCC in the US by Brand, 2013-2023 243

Figure 41: Sales for aRCC in the 5EU by Class, 2013-2023 249

Figure 42: Sales for aRCC in 5EU by Brand, 2013-2023 250

Figure 43: Sales for aRCC in the Japan by Class, 2013-2023 255

Figure 44: Sales for aRCC in Japan by Brand, 2013-2023 256

Figure 45: Sales for aRCC in the China by Class, 2013-2023 261

Figure 46: Sales for aRCC in China by Brand, 2013-2023 262

Additional Details

Publisher

Global Data

Publisher Information

Reference

27020 | GDHC88PIDR

Number of Pages

322

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 15% today! PharmaPoint: Renal Cell Carcinoma - Global Drug Forecast and Market Analysis to 2023
PharmaPoint: Renal Cell Carcinoma - Global Drug Forecast and Market Analysis to 2023SummaryRenal cel...
21 Apr 2016 by Global Data USD $9,346 (normally
USD $10,995)
More Info
SAVE 15% today! PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2024SummaryPsoriasis (PsO) is a...
13 Apr 2016 by Global Data USD $9,346 (normally
USD $10,995)
More Info
SAVE 15% today! PharmaPoint: Bipolar Disorder - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Bipolar Disorder - Global Drug Forecast and Market Analysis to 2024SummaryBipolar disor...
01 Mar 2016 by Global Data USD $9,346 (normally
USD $10,995)
More Info
SAVE 15% today! PharmaPoint: Hepatitis B Virus (HBV) Therapeutics - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Hepatitis B Virus (HBV) Therapeutics - Global Drug Forecast and Market Analysis to 2024...
01 Jan 2016 by Global Data USD $9,346 (normally
USD $10,995)
More Info
SAVE 15% today! PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Assessment to 2024
PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Assessment to 2024SummaryDry Eye Syn...
05 Nov 2015 by Global Data USD $9,346 (normally
USD $10,995)
More Info
SAVE 15% today! PharmaPoint: Atopic Dermatitis - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Atopic Dermatitis - Global Drug Forecast and Market Analysis to 2024SummaryAlthough the...
03 Nov 2015 by Global Data USD $9,346 (normally
USD $10,995)
More Info
SAVE 15% today! PharmaPoint: Multiple Myeloma - Global Drug Forecast and Market Analysis to 2023
PharmaPoint: Multiple Myeloma - Global Drug Forecast and Market Analysis to 2023SummaryThe Multiple ...
01 Nov 2015 by Global Data USD $9,346 (normally
USD $10,995)
More Info
SAVE 15% today! PharmaPoint: Peripheral Artery Disease - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Peripheral Artery Disease - Global Drug Forecast and Market Analysis to 2024SummaryIn t...
01 Oct 2015 by Global Data USD $9,346 (normally
USD $10,995)
More Info
SAVE 15% today! PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2024SummaryMultiple Sc...
10 Sep 2015 by Global Data USD $9,346 (normally
USD $10,995)
More Info
SAVE 15% today! PharmaPoint: Allergic Rhinitis - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Allergic Rhinitis - Global Drug Forecast and Market Analysis to 2024SummaryAllergic Rhi...
01 Sep 2015 by Global Data USD $9,346 (normally
USD $10,995)
More Info

This report is published by Global Data

Download Free Report Summary PDF

PharmaPoint: Renal Cell Carcinoma - Global Drug Forecast and Market Analysis to 2023 [Published by Global Data] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...